Efficacy and safety of neoadjuvant S-1-based chemoradiotherapy in resectable and borderline-resectable pancreatic cancer: a long-term follow-up study
S-1-based NACRT is safe and yields acceptable long-term outcomes for patients with resectable or borderline-resectable PDAC.
Authors
- Koichi Aiura
- Gaku Shimane (ORCID: https://orcid.org/0000-0002-7123-239X)
- Shutaro Hori (ORCID: https://orcid.org/0000-0001-9213-0758)
- Junichi Fukada (ORCID: https://orcid.org/0000-0002-0015-2341)
- Yutaka Endo (ORCID: https://orcid.org/0000-0001-7187-0124)
- Yohei Masugi (ORCID: https://orcid.org/0000-0002-6952-4043)
- Minoru Kitago
- Yutaka Nakano (ORCID: https://orcid.org/0000-0003-3228-3474)
- Masayuki Tanaka (ORCID: https://orcid.org/0000-0003-0335-3912)
- Yasushi Hasegawa (ORCID: https://orcid.org/0000-0002-4990-0419)
- Yuta Abe (ORCID: https://orcid.org/0000-0002-5840-8901)
- Hiroshi Yagi (ORCID: https://orcid.org/0000-0003-3295-2068)
- Yuko Kitagawa
Institutions
- Keio University (JP)
Publication Details
- Journal
- World Journal of Surgical Oncology
- Published
- 2024-12-20
- DOI
- https://doi.org/10.1186/s12957-024-03609-w
- Citations
- 2
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 0.57
Funders
- Keio University